The Different Types of Wegovy Available in the UK

The myth worth clearing up: 'Wegovy' is not a single product

Most people searching for information about Wegovy assume there is one product, one pen, one routine. That was true until 2026. There are now two separate licensed formats, and they are meaningfully different — not just cosmetically. Conflating them can lead to confusion about what a prescription actually covers, what side effects to expect in the first weeks, and how to take it correctly.

A second layer of confusion comes from semaglutide having other brand names. Semaglutide is also sold as Ozempic and Rybelsus, but those are licensed for type 2 diabetes, not weight management. If a result in your search mentions one of those names in a weight-loss context, it is worth pausing. The MHRA is clear that Ozempic is not indicated for weight loss. The Wegovy drug type (GLP-1 receptor agonist) is shared with Ozempic, but the licensed use, the dose, and the regulatory status are not interchangeable. A quick check of the product name against the NHS medicines pages takes under a minute and tells you immediately which licence applies.

With that cleared up, here is what the two Wegovy formats actually are.

Wegovy injection: the original once-weekly pen

The Wegovy injection is a pre-filled subcutaneous pen. You inject it once a week, rotating between the abdomen, thigh or upper arm. Treatment starts at 0.25 mg and is titrated upward by a prescriber through 0.5 mg, 1.0 mg and 1.7 mg before reaching the 2.4 mg maintenance dose — each step at roughly four-week intervals. The prescriber decides the pace; the Patient Information Leaflet covers the detail.

In April 2026, the MHRA also approved a dedicated single-dose 7.2 mg pen, designed for adults with a BMI of 30 or above. It uses an auto-dosing mechanism with a covered needle that locks after use. The 7.2 mg dose is the maximum; the titration pathway still starts at 0.25 mg. Trial data at the 7.2 mg level reported around 20.7% average weight loss over 72 weeks, which brings it closer to the results seen with tirzepatide. You can read the broader evidence picture on our Wegovy overview page.

The injection pen requires refrigeration between 2 and 8°C. The SmPC (available via the eMC) gives the precise window for room-temperature storage when travelling; always check it rather than relying on general estimates.

Wegovy tablet: the newer daily option

On 11 June 2026, the MHRA approved oral semaglutide tablets under the Wegovy brand name, making the UK the first country in Europe to license them for weight management. The tablet contains the same active ingredient as the injection but is co-formulated with an absorption enhancer called SNAC, which allows semaglutide to pass through the stomach lining.

The schedule starts at 1.5 mg daily and escalates through 4 mg and 9 mg to a 25 mg maintenance dose, spending at least a month at each level. How you take it matters: first thing in the morning, with a small amount of plain water (roughly up to 120 ml) on a completely empty stomach. You then wait at least 30 minutes before eating, drinking anything else (including coffee), or taking other oral medicines. Swallow the tablet whole.

One practical advantage is storage. No refrigeration is needed, which makes it simpler to manage when travelling. The licensed population is adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition. In the OASIS 4 phase 3 trial (307 adults without diabetes, followed for 64 weeks) participants lost an average of around 13.6% of their body weight compared with approximately 2.4% on placebo. Among those who stayed fully adherent to treatment throughout the trial, the average loss was closer to 17%. There is more detail on how the different semaglutide types compare if you want to look at the formats side by side.

The tablet is not currently available on the NHS; a NICE appraisal process would be needed first. At launch it is a private prescription only. If you are already established on the 2.4 mg injection, moving to the 25 mg tablet is possible subject to clinical review, not a decision to make unilaterally.

Choosing between the formats: what a prescriber considers

Neither format is objectively better; the right one depends on the individual. Some people find injections straightforward once they have done the first one. Others strongly prefer a tablet, particularly if they take other daily oral medicines or travel frequently. Absorption differences between the two formats mean the side-effect profiles can feel slightly different in the early weeks, though both share the same GI-led pattern, nausea, loose stools and indigestion being the most commonly reported. As the NHS semaglutide page notes, these effects tend to be most noticeable after starting or increasing the dose and often settle within days to a couple of weeks.

Cost context also factors into real decisions. Both formats are private-prescription medicines with pricing that reflects clinical oversight, pharmacy dispensing and delivery. There is a useful breakdown of what legitimately goes into the price on the Wegovy cost and access page, which is worth reading before comparing headline figures between providers. What a headline price excludes (consultation fees, aftercare, delivery) can shift the real comparison significantly.

If you are unsure which Wegovy type might suit your circumstances, the semaglutide type guide covers the licensed landscape in more detail. The prescribers at nume review every consultation personally (no automated decision-making) and the format question is part of what gets discussed. If you would like that review, check your eligibility and start a free consultation.